Meeting
2019 ASCO Annual Meeting
Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer.
Authors
Steven H. Lin
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Steven H. Lin , Yan Lin , Isabel Mok , Jenean A. Young , See Phan , Alan Sandler , Vassiliki Papadimitrakopoulou , John Heymach , Anne S. Tsao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02525757
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8512)
DOI
10.1200/JCO.2019.37.15_suppl.8512
Abstract #
8512
Poster Bd #
268
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III non–small cell lung cancer: TORG1937 (DATE study).
First Author: Shinji Nakamichi
Poster
2022 ASCO Annual Meeting
Monitoring engorgement of phagocytic circulating stromal cells during chemo-radiotherapy induction predicts survival in unresectable stage 2/3 NSCLC.
First Author: Kirby P Gardner
Poster
2023 ASCO Annual Meeting
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
First Author: Mustafa Özgüroğlu
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse